As we begin to reopen Rush University Medical Center for elective procedures and in-person care, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.

Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Treatment Study for Patients with Newly Diagnosed B-Lymphoblastic Leukemia or B-Lineage Lymphoblastic Lymphoma

Clinical Trial Title: 
Treatment of patients with newly diagnosed standard risk B-lymphoblastic leukemia (B-ALL) or localized B-lineage lymphoblastic lymphoma (B-LLy).
Clinical Trial Protocol ID: 
10080902-IRB01-AM09
Clinical Trial Investigator Name: 
Mary Lou Schmidt, MD
Clinical Trial Protocol Description: 

To determine if a maintenance regimen containing weekly oral methotrexate at 40mg/m2/week will result in an improved disease free survival (DFS) compared to that containing weekly oral methotrexate at 20mg/m2/week in the average risk subset of patients with standard risk B-ALL.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have newly diagnosed NCI standard risk B-ALL or B-LLy Murphy Stages I or II.
  • Have an initial white blood cell count < 50,000/uL.

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Blood Disorders and Hematologic Cancers
Contact Phone: 
(312) 355-0741
Contact Name: 
Nitin Sane